⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of RemeGen and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
RemeGen
↗Yantai, China
RemeGen is a leading innovative biopharmaceutical company based in China, focused on the discovery, development, and commercialization of proprietary biologics. The company specializes in autoimmune diseases, oncology, and ophthalmology, leveraging advanced technology platforms including antibody and fusion protein engineering, antibody-drug conjugates (ADCs), and multispecific antibodies.
With a fully integrated R&D and manufacturing infrastructure, RemeGen has successfully brought multiple innovative drugs to market, including Telitacicept (RC18) and Disitamab Vedotin (RC48). The company maintains a global presence with R&D centers and offices in China and the United States, and is dual-listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange STAR Market.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology, Autoimmune, Ophthalmology
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$200M-$300M
Founded:2008
Ownership:public
Status:operating
FUNDING
Total Raised:$100M (initial)
Investors:Lilly Asia Ventures
STOCK
Exchange:HKEX, SSE
Ticker:9995.HK, 688331.SH
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Fusion protein, mAb, ADC, Bispecific antibody
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AbbVie (RC148 licensing), Santen (RC28-E licensing), Vor Bio (Telitacicept licensing), Pfizer (Disitamab Vedotin rights)
COMPETITION
Position:Leader
Competitors:BeiGene, Jazz Pharmaceuticals, Sana Biotechnology
LEADERSHIP
Key Executives:
Jianmin Fang - CEO
Weidong Wang - Chairman
Scientific Founders:Jianmin Fang, Weidong Wang
LINKS
Website:remegen.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with RemeGen. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.